Answers are grounded in this paper and cite their sources.
This review highlights biomarkers and neuroimaging techniques for Alzheimer's diagnosis, emphasizing machine learning implications.
Alzheimer's disease (AD) is a progressive neurological disorder characterized by memory loss, cognitive decline, and neurodegeneration. Early diagnosis through biomarkers is crucial for improving treatment outcomes and managing the disease. This review highlights invasive and non-invasive biomarkers for AD diagnosis which includes cerebrospinal fluid, blood-based, exosomal, and fluid-based biomarkers. Neuroimaging techniques, such as structural MRI and functional imaging, are also discussed. Recent advancements in blood-based biomarker technology and emerging AI and machine learning techniques offer promising avenues for early AD diagnosis. Future non-invasive diagnostic tools which includes wearable sensors may aid in early detection and personalized treatments.
No takes yet. Share an insight, caveat, or question.
Unsa Saleem (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: